New lease of life for asthmatics by Accentia Biopharmaceuticals

"MDIs have been around for about 50 years. But MD Turbo is the first companion product to solve two of the biggest challenges facing MDI users: coordination of inhaler actuation with patient's breath, and the accounting of how much medication is left in the inhaler. We are all very excited about introducing a new product to the market that can improve the quality of care," said an excited Gil Mott, President and Chief Executive Officer of Respirics Inc.

More than 40 million MDIs are prescribed each year in the United States alone.

So it would be a lease of fresh air for many asthma patients.